Cingulate, Inc. (CING)

Over the past six months, several events have impacted Cingulate, Inc.'s stock price. The FDA accepted Cingulate's NDA for CTx-1301, setting a PDUFA target action date of May 31, 2026. Cingulate presented positive Phase 3 results for CTx-1301 in pediatric ADHD, demonstrating statistically significant efficacy and entire active-day symptom control. Bryan Downey was appointed as Chief Commercial Officer, and the company completed a $6 million financing transaction. Cingulate reported its Third Quarter 2025 financial results. Ascendiant Capital maintained a "Buy" recommendation for Cingulate. Cingulate closed a $12 million private investment in public equity (PIPE) financing. Cingulate reported its Fourth Quarter and Full Year 2025 financial results and announced a U.S. Patent Notice of Allowance and additional European patents for CTx-1301. Analysts increased the price target for CING by 7.1% to US$29.30. Cingulate's share price increased by 63.29%.

As a clinical-stage biopharmaceutical company, Cingulate, Inc. currently has product candidates in various stages of development and regulatory review, rather than commercially available products; therefore, there is no established demand seasonality for its products or services at this time. The company is preparing for a potential commercial launch of CTx-1301 around mid to late-2026, subject to FDA approval. The ADHD medication market, which Cingulate is targeting, has shown consistent growth, indicating a strong underlying market demand for such products.

Cingulate, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation pharmaceutical products using its proprietary Precision Timed Release™ drug delivery platform technology. The company operates within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Preparations industry, focusing on conditions with burdensome daily dosing regimens and suboptimal therapeutic coverage, with an initial emphasis on ADHD and anxiety. Its major product candidates include CTx-1301 (dexmethylphenidate HCl), a once-daily, extended-release stimulant therapy in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults, CTx-1302 (dextroamphetamine), also in development for the treatment of ADHD, intended for all patient segments and CTx-2103 (buspirone), in the formulation stage for the treatment of anxiety disorders.

Cingulate, Inc. is headquartered in Kansas City, Kansas, United States.

Cingulate's brand reputation in the past year has largely been shaped by its progress in clinical development and regulatory milestones. Positive Phase 3 clinical trial results for CTx-1301 in pediatric ADHD and the FDA's acceptance of the NDA for CTx-1301 have positively impacted its scientific credibility and standing within the biopharmaceutical community. The granting of U.S. and European patents for CTx-1301 further strengthens its intellectual property and innovative image. The company's strategic financings also demonstrate investor confidence. However, reported net losses, such as the $7.3 million net loss for the three months ended September 30, 2025, and a $22.4 million net loss for the full year 2025, could be perceived negatively from a financial performance perspective.

Cingulate Inc. has a mixed ownership structure comprising institutional, retail, and individual investors. Approximately 0.86% to 4.78% of the company's stock is held by institutional investors, 1.48% to 9.53% by insiders, and a significant portion, around 80.97% to 94.77%, by public companies and individual investors (retail). Major institutional owners include Vanguard Group Inc, Kestra Advisory Services, LLC, Geode Capital Management, Llc, DRW Securities, LLC, UBS Group AG, XTX Topco Ltd, Quadrature Capital Ltd, Northern Trust Corp, LPL Financial LLC and Quantum Private Wealth, LLC.